ABSTRACT
The goal of the work toassessment of efficacy and safety of allergen immunotherapy in children and adults with allergic rhinitis, and to conduct a comparative assessment of the effectiveness of subcutaneous (SCIT) and sublingual variant (SLIT) immunotherapy. We have analyzed the medical documentation of patients during the application of allergen immunotherapy for 5 years in 710 patients with allergic rhinitis (AR). According to the results of the validated scale analysis, the clinical efficacy parameters of SCIT and SLIT after a year, 2, 3, and also after 4 and 5 years of therapy were comparable in both children and adults. At the same time, both SCIT and SLIT showed comparable efficacy in both adults and children. Systemic side effects were observed in 10% of children on SCIT and in 7% of children on SLIT. The frequency of systemic reactions in adults was 6% for SCIT, for SLIT it did not exceed 2%.
